XML 44 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information (Tables)
 6 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals
Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
 
Quarter Ended September 30,
 
Six Months Ended September 30,
(In millions)
2016
 
2015
 
2016
 
2015
Revenues
 
 
 
 
 
 
 
Distribution Solutions (1)
 
 
 
 
 
 
 
North America pharmaceutical distribution and services
$
41,375

 
$
40,603

 
$
82,586

 
$
80,135

International pharmaceutical distribution and services
6,271

 
5,866

 
12,601

 
11,704

Medical-Surgical distribution and services
1,631

 
1,571

 
3,099

 
3,011

Total Distribution Solutions
49,277

 
48,040

 
98,286

 
94,850

 
 
 
 
 
 
 
 
Technology Solutions - products and services
680

 
721

 
1,404

 
1,457

Total Revenues
$
49,957

 
$
48,761

 
$
99,690

 
$
96,307

 
 
 
 
 
 
 
 
Operating profit
 
 
 
 
 
 
 
Distribution Solutions (2) (3)
$
851

 
$
926

 
$
1,779

 
$
1,836

Technology Solutions (4) (5)
(174
)
 
146

 
(6
)
 
304

Total
677

 
1,072

 
1,773

 
2,140

Corporate Expenses, Net
(74
)
 
(101
)
 
(179
)
 
(225
)
Interest Expense
(78
)
 
(91
)
 
(157
)
 
(180
)
Income from Continuing Operations Before Income Taxes
$
525

 
$
880

 
$
1,437

 
$
1,735

(1)
Revenues derived from services represent less than 2% of this segment’s total revenues.
(2)
Distribution Solutions operating profit for the second quarter and first six months of 2017 include pre-tax credits of $43 million and pre-tax charges of $4 million related to our last-in, first-out (“LIFO”) method of accounting for inventories. The second quarter and first six months of 2016 include pre-tax LIFO charges of $91 million and $182 million. LIFO expense decreased in 2017 primarily due to the lower full year expectations for price increases.
(3)
The second quarter of 2016 includes a pre-tax gain of $52 million recognized from the sale of our ZEE Medical business, and the first six months of 2017 and 2016 include $142 million and $59 million of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers.
(4)
Technology Solutions operating profit for the first six months of 2016 includes a pre-tax gain of $51 million recognized from the 2016 first quarter sale of our nurse triage business.
(5)
The second quarter and first six months of 2017 include a non-cash pre-tax charge of $290 million for goodwill impairment related to the EIS reporting unit within our Technology Solutions segment.